

**BONESUPPORT HOLDING AB (publ) – Q3 2019 Interim Report –
invitation to conference call and webcast**

Lund, Sweden, 08.00 am CET, 30 October 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids, will publish its Q3 2019 interim report on the 7 November 2019 at 08.00 am CET.

The Company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English.

The dial-in numbers for the conference call are:

UK: + 44 333 300 92 71

SE: + 46 8 505 583 51

US: + 1 646 722 49 04

The presentation will be webcasted and can be accessed from the following web address:

<https://financialhearings.com/event/11697>

About BONESUPPORT™

BONESUPPORT™ (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform [CERAMENT](#). The Company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for [CERAMENT G](#) is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are [registered trademarks](#) of BONESUPPORT AB.

For more information contact:

BONESUPPORT AB

Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Press Release

Cord Communications

Charlotte Stjerngren

+46 (0) 708 76 87 87

charlotte.stjerngren@cordcom.se

www.cordcom.se